Mark H. O'Hara

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215)360-0735
Fax: (215)662-4646
Education:
BS (Biology - Molecular Genetics)
University of Rochester, 2004.
MD (Medicine)
Stony Brook School of Medicine, 2008.
Permanent link
 

Description of Itmat Expertise

Immunotherapy in cancer
Targeted therapy in cancer
Pancreatic cancer
Colon cancer
Cholangiocarcinoma
Neuroendocrine tumor
Phase 1 clinical trials

Description of Research Expertise

Pancreatic cancer, colorectal cancer, GI cancers, Phase 1

Selected Publications

Beatty GL, O'Hara MH: Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacology and Therapeutics 166: 30 - 39, October 2016.

O'Hara MH, Hamilton SR, O'Dwyer PJ: Molecular Triage Trials in Colorectal Cancer. The Cancer Journal 22(3): 218 - 222, May-June 2016.

O’Hara MH, Stashwick C, Haas AR, Tanyi JL: Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8(4), April 2016.

Clark A, Karasic T, DeMichele A, Vaughn D, O’Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O’Dwyer P: Palbociclib (PD0332991), a selective and potent cyclin-dependent kinase inhibitor: Pharmacodynamic results and clinical development. JAMA Oncology 2(2): 253 - 260, February 2016.

O'Hara MH, Giantonio BJ: Metastatic Colorectal Cancer. Multidisciplinary Management of Gastrointestinal Cancers. Weijing Sun (eds.). World Scientific, 2016.

O’Hara MH, Gallagher M, Teitelbaum UR, Giantonio BJ, Damjanov N, Loaiza-Bonilla A, Amaravadi RK, Heitjan DF, Vasilevskaya IA, Von Hoff DD, Ramanathan RK, Laheru DA, Acosta Ade J, Velculescu VE, O’Dwyer PJ. : Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma. American Society of Clinical Oncology Annual Conference, Chicago, IL e15213, June 2015.

O'Dwyer PJ, O'Hara MH, Sherman M, Johnston K, Anderson A, Valdivieso F, Gates J, Feldman MD, Downes M, Evans R, Drebin J: A randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to target the microenvironment in resectable pancreatic cancer: A SU2C trial. American Society of Clinical Oncology Annual Conference, Chicago, IL June 2015.

O'Hara MH, Loaiza-Bonilla A, Redlinger M, Damjanov N, Teitelbaum UR, Vasilevskaya I, Rosen MA, Heitjan DF, Amaravadi RK, O'Dwyer PJ: Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. American Society of Clinical Oncology Annual Conference, Chicago, IL June 2015.

O'Hara MH*, Beatty GL*, Nelson AM, McGarvey M, Torigian DA, Lacey SF, Melenhorst JJ, Levine B, Plesa G, June CH: Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. American Society of Clinical Oncology Annual Conference, Chicago, IL, oral presentation June 2015.

O'Hara MH, Edmonds CE, Farwell MD, Perini RF, Pryma DA, Teitelbaum UR, Giantonio BJ, Damjanov N, Lal P, Feldman MD, Zheng P, Gallagher M, DeMichele A, Vaughn DJ, Mankoff D, O'Dwyer PJ: Phase II Pharmacodynamic Trial of Palbociclib in Patients with KRAS Mutant Colorectal Cancer. J Clin Oncol 33(suppl 3): abstr 626, January 2015.

back to top
Last updated: 12/12/2016
The Trustees of the University of Pennsylvania